The phenotypic landscape of the TP53 p.Arg337His mutation in pediatric cancers: a scoping review protocol

Authors

DOI:

https://doi.org/10.33448/rsd-v14i11.49701

Keywords:

Genetic predisposition to disease, Neoplasms, Child, Li-Fraumeni syndrome, Genetics, Adolescent.

Abstract

The TP53 p.Arg337His is a founder mutation that exists at a very high frequency in Southern and Southeastern Brazil. Adrenocortical and plexus choroides carcinomas are highly associated with this variant. The present scoping review protocol aimed to map health-related literature searching for pediatric cancer related to the TP53 p.Arg337His. Methods: A scoping review protocol is presented in this article, conducted adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guideline. Six databases, an electronic repository, and additional sources were searched using keywords and text words. The review team consists of three independent screeners. Two screeners will do the initial title and abstract screening for all studies retrieved by the search strategy and then the full text screening phase. Reference lists of included studies will be screened, and data will be independently extracted by the review team. Results will be analyzed qualitatively and quantitatively. Ethics and dissemination: Ethical approval is not necessary, since the study does not involve human participants. Findings will be disseminated through publication at scientific journals and conferences.

References

Achatz, M. I. W., Olivier, M., Calvez, F. Le, Martel-Planche, G., Lopes, A., Rossi, B. M., Ashton-Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., Rocha, J. C. C. Da, Vettore, A. L., & Hainaut, P. (2007). The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Letters, 245(1–2), 96-102. https://doi.org/10.1016/j.canlet.2005.12.039

Achatz, M. I., & Zambetti, G. P. (2016). The inherited p53 mutation in the Brazilian population. Cold Spring Harbor Perspectives in Medicine, 6(12). https://doi.org/10.1101/cshperspect.a026195

Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. (2024). JBI Manual for Evidence Synthesis. JBI. Available from: https://synthesismanual.jbi.global. https://doi.org/10.46658/JBIMES-24-01.

Cohen, J. (1960). A coefficient of agreement for nominal scales. Educational and Psychological Measurement. Educational and Psychological Measurement, 20(1). https://doi.org/10.1177/001316446002000104.

Custódio, G., Parise, G. A., Kaesel Filho, N., Komechen, H., Sabbaga, C. C., Rosati, R., Grisa, L., Parise, I. Z. S., Pianovski, M. A. D., Fiori, C. M. C. M., Ledesma, J. A., Barbosa, J. R. S., Figueiredo, F. R. O., Sade, E. R., Ibañez, H., Arram, S. B. I., Stinghen, S. T., Mengarelli, L. R., Figueiredo, M. M. O., … Figueiredo, B. C. (2013). Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. Journal of Clinical Oncology, 31(20), 2619-2626. https://doi.org/10.1200/JCO.2012.46.3711

Custodio, G., Taques, G. R., Figueiredo, B. C., Gugelmin, E. S., Figueiredo, M. M. O., Watanabe, F., Pontarolo, R., Lalli, E., & Torres, L. F. B. (2011). Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS ONE, 6(3), e18015. https://doi.org/10.1371/journal.pone.0018015

Foster, E. D., & Deardorff, A. (2017). Open Science Framework (OSF). Journal of the Medical Library Association, 105(2), 203-206. https://doi.org/10.5195/jmla.2017.88

Frebourg, T., Bajalica Lagercrantz, S., Oliveira, C., Magenheim, R., Evans, D. G., Hoogerbrugge, N., Ligtenberg, M., Kets, M., Oostenbrink, R., Sijmons, R., Woodward, E., Tischkowitz, M., Maher, E., Ferner, R. E., Aretz, S., Spier, I., Steinke-Lange, V., Holinski-Feder, E., Schröck, E., … Hietala, M. (2020). Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes. European Journal of Human Genetics, 28(10), 1379-1386. https://doi.org/10.1038/s41431-020-0638-4

Jeffers, J. R., Pinto, E. M., Rehg, J. E., Clay, M. R., Wang, J., Neale, G., Heath, R. J., Lozano, G., Lalli, E., Figueiredo, B. C., Pappo, A. S., Rodriguez-Galindo, C., Chen, W., Pounds, S., Ribeiro, R. C., & Zambetti, G. P. (2021). The common germline TP53-R337H mutation is hypomorphic and confers incomplete penetrance and late tumor onset in a mouse model A C. Cancer Research, 81(9). https://doi.org/10.1158/0008-5472.CAN-20-1750

Kratz, C. P., Achatz, M. I., Brugieres, L., Frebourg, T., Garber, J. E., Greer, M. L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., Mullighan, C. G., Onel, K., Pajtler, K. W., Pfister, S. M., Savage, S. A., Schiffman, J. D., Schneider, K. A., Strong, L. C., Evans, D. G. R., … Malkin, D. (2017). Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clinical Cancer Research, 23(11), e38-e45. https://doi.org/10.1158/1078-0432.CCR-17-0408

Kratz, C. P., Freycon, C., Maxwell, K. N., Nichols, K. E., Schiffman, J. D., Evans, D. G., Achatz, M. I., Savage, S. A., Weitzel, J. N., Garber, J. E., Hainaut, P., & Malkin, D. (2021). Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 7(12), 1800-1805. https://doi.org/10.1001/jamaoncol.2021.4398

Magalhães, A. T.; Borges, K. S.; Sousa, G. R.; Brandalise, S. R.; Seidinger, A. L.; Scrideli, C. A.; Oba-Shinjo, S. M.; Yunes J. A.; Tone, L. G. (2019). The TP53 p.Arg337His mutation is uncommon in a Brazilian cohort of pediatric patients diagnosed with ependymoma. Neurological Sciences, 41(3), 691–694, nov. 2019. DOI: https://doi.org/10.1007/s10072-019-04112-x.

Mattos, S. M., Cestari, V. R. F., & Moreira, T. M. M. (2023). Scoping protocol review: PRISMA-ScR guide refinement. Rev Enferm UFPI, 12(1), e3062. https://doi.org/10.26694/reufpi.v12i1.3062

McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016). PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. Journal of Clinical Epidemiology, 75(1), 40-6. https://doi.org/10.1016/j.jclinepi.2016.01.021

Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1). https://doi.org/10.1186/s13643-016-0384-4

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The BMJ 372(71). https://doi.org/10.1136/bmj.n71

Pinto, E. M., Fridman, C., Figueiredo, B. C., Salvador, H., Teixeira, M. R., Pinto, C., Pinheiro, M., Kratz, C. P., Lavarino, C., Legal, E. A. M. F., Le, A., Kelly, G., Koeppe, E., Stoffel, E. M., Breen, K., Hahner, S., Heinze, B., Techavichit, P., Krause, A., … Zambetti, G. P. (2024). Multiple TP53 p.Arg337His haplotypes and implications for tumor susceptibility. Human Genetics and Genomics Advances, 5(1), 100244. https://doi.org/10.1016/j.xhgg.2023.100244.

Pinto, E. M., & Zambetti, G. P. (2020). What 20 years of research has taught us about the TP53 p.Arg337His mutation. Cancer. 126(21), 4619-4805 https://doi.org/10.1002/cncr.33143

Souza, M. A. R. de, Wall, M. L., Thuler, A. C. de M. C., Lowen, I. M. V., & Peres, A. M. (2018). O uso do software IRAMUTEQ na análise de dados em pesquisas qualitativas. Revista da Escola de Enfermagem da USP, 52, e03353. https://doi.org/10.1590/s1980-220x2017015003353

Seidinger, A. L.; Forte, F. P.; Mastellaro, M. J.; Cardinalli, I. A.; Zambaldi, L. G.; Aguiar, S. S.; Yunes, J. A. (2015). Occurrence of Neuroblastoma among TP53 p.Arg337His Carriers. PLOS ONE, 10(10), p. e0140356. https://doi.org/10.1371/journal.pone.0140356.

Seidinger, A. L.; Mastellaro, M. J.; Fortes, F. P.; Assumpção, J. G.; Cardinalli, I. A.; Ganazza, M. A.; Ribeiro, R. C. R.; Brandalise, S. R.; Aguiar, S. S. (2010). Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil. Cancer, 117(10), 2228–2235. https://doi.org/10.1002/cncr.25826.

Villani, A., Davidson, S., Kanwar, N., Lo, W. W., Li, Y., Cohen-Gogo, S., Fuligni, F., Edward, L. M., Light, N., Layeghifard, M., Harripaul, R., Waldman, L., Gallinger, B., Comitani, F., Brunga, L., Hayes, R., Anderson, N. D., Ramani, A. K., Yuki, K. E., … Shlien, A. (2023). The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations. Nature Cancer, 4(2), 203-221. https://doi.org/10.1038/s43018-022-00474-y

Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., Novokmet, A., Finlay, J., & Malkin, D. (2011). Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study. The Lancet Oncology, 12(6), 559-567. https://doi.org/10.1016/S1470-2045(11)70119-X

World Health Organization (2021). Cancer in children. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cancer-in-children

Downloads

Published

2025-11-15

Issue

Section

Note Preview

How to Cite

The phenotypic landscape of the TP53 p.Arg337His mutation in pediatric cancers: a scoping review protocol. Research, Society and Development, [S. l.], v. 14, n. 11, p. e115141149701, 2025. DOI: 10.33448/rsd-v14i11.49701. Disponível em: https://rsdjournal.org/rsd/article/view/49701. Acesso em: 5 dec. 2025.